Platelet production pathway modulation

"Platelet production pathway modulation" refers to any therapeutic or experimental method that alters the biological pathways regulating platelet generation (thrombopoiesis) from megakaryocytes. Thrombopoiesis involves complex signaling cascades—including thrombopoietin receptor (MPL), Janus kinases, integrins, mechanosensitive channels (TRPV4), and cytoskeletal dynamics regulated by tubulin proteins and Hippo pathway members—that collectively control megakaryocyte maturation, proplatelet formation, and platelet release[1][4][5]. Pharmaceutical agents targeting these pathways are used to increase platelet count in thrombocytopenia (such as thrombopoietin receptor agonists eltrombopag, romiplostim) or to reduce platelet production in conditions of pathologic thrombocytosis (such as hydroxyurea, anagrelide)[4][5]. Because the term denotes a broad biological process and not an individual molecular entity, it is not considered a canonical therapeutic target itself, but rather encompasses interventions directed at defined molecular targets within the pathway.

Other names

Platelet biogenesis modulationThrombopoiesis regulationPlatelet generation pathway targeting

Thrombopoietin receptor agonism; Inhibition of megakaryocyte proliferation or maturation; Inhibition of platelet activation or aggregation; Modulation of signaling pathways in megakaryocytes (e.g. TRPV4 activation, PI3K/Akt, MAPK/ERK, Hippo pathway)